Fig. 6From: Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and NorwayCost-Effectiveness Acceptability Curve (CEAC). Note: WTP levels of EUR 20,000 and EUR 30,000 are indicated by the grey vertical linesBack to article page